Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.
The genome diversity of RNA viruses allows for rapid adaptation to a wide variety of adverse conditions. Accordingly, viruses can escape inhibition by most antiviral compounds targeting either viral or host factors. Here we exploited the capacity of RNA viruses for rapid adaptation to explore the evolutionary constraints of chaperone-mediated protein folding. We hypothesized that inhibiting a host molecular chaperone required for folding of a viral protein would force the virus to evolve an alternate folding strategy. We identified the chaperone Hsp90 as an essential factor for folding and maturation of picornavirus capsid proteins. Pharmacological inhibition of Hsp90 impaired the replication of poliovirus, rhinovirus, and coxsackievirus in cell culture. Strikingly, anti-Hsp90 treatment did not yield drug-resistant viruses, suggesting that the complexity of capsid folding precludes the emergence of alternate folding pathways. These results reveal tight evolutionary constraints on chaperone-mediated protein folding, which may be exploited for viral inhibition in vivo. Indeed, Hsp90 inhibitors drastically reduced poliovirus replication in infected animals without the emergence of drug-resistant escape mutants. We propose that targeting folding of viral proteins may provide a general antiviral strategy that is refractory to development of drug resistance.
Geller
Ron
R
Department of Biological Sciences, Stanford University, Stanford, California 94305, USA.
Vignuzzi
Marco
M
Andino
Raul
R
Frydman
Judith
J
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D016227:Benzoquinones / Q000494:pharmacology*; D036022:Capsid Proteins / Q000378:metabolism; D002460:Cell Line; D002522:Chlorocebus aethiops; D024882:Drug Resistance, Viral; D019143:Evolution, Molecular; D005260:Female; D005347:Fibroblasts / Q000821:virology; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D010849:Picornaviridae / Q000187:drug effects*; D010850:Picornaviridae Infections / Q000188:drug therapy / Q000821:virology; D017510:Protein Folding; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D016227:Benzoquinones; D036022:Capsid Proteins; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C112765:tanespimycin; C001277:geldanamycin